EP
BBIO icon

Essential Partners’s BridgeBio Pharma BBIO Stock Holding History

Essential Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.86K Sell
119
-186
-61% -$13K ﹤0.01% 1270
2026
Q1 		$22.6K Hold
305
– – 0.01% 879
2025
Q4 		$23.3K Hold
305
– – 0.01% 851
2025
Q3 		$15.8K Hold
305
– – 0.01% 982
2025
Q2 		$13.2K Buy
+305
New +$11.1K 0.01% 773

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Essential Partners's BBIO Position: Q2 2026 in Review

Essential Partners reduced its BridgeBio Pharma (BBIO) stake by 61% in Q2 2026, selling an estimated $13K and leaving 119 shares worth $8.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Essential Partners first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $23.3K in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Essential Partners held 119 shares of BridgeBio Pharma worth $8.86K as of Q2 2026.
  • Essential Partners sold 186 BridgeBio Pharma shares in Q2 2026, an estimated $13K.
  • BridgeBio Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1270 holding.
  • Essential Partners first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's BridgeBio Pharma position peaked at $23.3K in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.